Pharmanovia Sustainability Profile
Pharmanovia, a leading pharmaceutical company headquartered in Great Britain, has established itself as a key player in the global healthcare landscape since its founding in 2015. With a focus on specialty pharmaceuticals, the company operates across Europe, the Middle East, and Africa, delivering innovative solutions that address unmet medical needs. Pharmanovia's core offerings include a diverse portfolio of products in therapeutic areas such as oncology, neurology, and rare diseases. What sets Pharmanovia apart is its commitment to enhancing patient access to high-quality medicines through strategic partnerships and a robust supply chain. The company has achieved notable milestones, including the successful launch of several proprietary products, solidifying its market position as a trusted provider in the pharmaceutical industry.
DitchCarbon Score
How does Pharmanovia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanovia's score of 30 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmanovia's reported carbon emissions
In 2023, Pharmanovia reported total carbon emissions of approximately 15,827,000 kg CO2e. This figure includes 60,000 kg CO2e from Scope 1 emissions and 4,493,000 kg CO2e from Scope 3 emissions, which primarily stem from purchased goods and services (about 11,274,000 kg CO2e) and upstream transportation and distribution (approximately 2,996,000 kg CO2e). Comparatively, in 2022, the company recorded total emissions of about 12,477,000 kg CO2e, with Scope 1 emissions remaining constant at 60,000 kg CO2e, while Scope 2 emissions were reported at 3,000 kg CO2e. The Scope 3 emissions for that year were approximately 3,172,000 kg CO2e. Pharmanovia has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The emissions data is not cascaded from any parent organization, indicating that these figures are solely from Pharmanovia itself. Overall, Pharmanovia's emissions profile highlights a significant reliance on Scope 3 emissions, particularly from their supply chain, which is a common trend in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 51,000 | 00,000 | 00,000 |
| Scope 2 | 76,000 | 0,000 | - |
| Scope 3 | 9,998,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Pharmanovia's Industry?
How Carbon Intensive is Pharmanovia's Location?
Pharmanovia's Scope 3 Categories Breakdown
Pharmanovia's Scope 3 emissions, which increased by 42% last year and decreased by approximately 55% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 251% of Scope 3 emissions.
Top Scope 3 Categories
Pharmanovia's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmanovia has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
